all report title image
  • Published On : Mar 2022
  • Code : CMI4983
  • Industry : Pharmaceutical
  • Pages : 156
  • Formats :

P2Y12 is a chemoreceptor for adenosine diphosphate (ADP) that belongs to the Gi class of a group of G protein-coupled (GPCR) purinergic receptors. The P2Y12 receptor is involved in platelet aggregation and is thus a biological target for the treatment of thromboembolisms and other clotting disorders. P2Y12 receptor blocker group of drugs includes clopidogrel, ticlopidine, ticagrelor, prasugrel, cangrelor, and others.

The U.S. P2Y12 inhibitors market is estimated to have around US$ 215.7 Mn in 2021, and is expected to exhibit a CAGR of 3.8% during the forecast period (2021-2028).

Figure 1. U.S. P2Y12 Inhibitors Market Share (%) in Terms of Value, By Drug, 2021

U.S. P2Y12 Inhibitors  | Coherent Market Insights

The rising incidence of cardiovascular diseases is expected to drive the market growth during the forecast period.

The rising incidence of cardiovascular diseases in the U.S. is expected to drive the growth of the U.S. P2Y12 Inhibitors market over the forecast period. For instance, according to the data published in Centers for Disease Control and Prevention in September 2021, it is estimated that heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the U.S. Moreover, about 659,000 people in the U.S die from heart disease each year.

CMI table icon

U.S. P2Y12 Inhibitors Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 215.7 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 3.8% 2028 Value Projection: US$ 279.6 Mn
Geographies covered:
  • North America: U.S.
Segments covered:
  • By Drug: Clopidogrel, Ticlopidine, Ticagrelor, Prasugrel, Cangrelor, Others
  • By Route of Administration: Oral, Intravenous
  • By Application: Angioplasty, Arterial Thrombosis, Percutaneous Coronary Interventions, Myocardial Infarction, Others
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Mylan N.V., Bristol-Myers Squibb, Dr Reddy's Laboratories, Teva Pharmaceuticals USA, Inc.,  AstraZeneca, Genentech, Eli Lilly and Company, Panacea Biotec, CHIESI USA, Inc., Lupin, Cipla, and Biocon

Growth Drivers:
  • Rising incidence of cardiovascular diseases
  • Increasing product approvals Robust product pipeline
Restraints & Challenges:
  • Potential side effects of drugs 

Figure 2. U.S. P2Y12 Inhibitors Market Share (%), By Distribution Channel, 2021

U.S. P2Y12 Inhibitors  | Coherent Market Insights

Increasing product approvals is expected to drive the market growth during the forecast period.

Key players operating in the market are focusing on product approvals which is expected to drive the market growth over forecast period. For instance, in June 2020, AstraZeneca, a biopharmaceutical company’s, Brilinta (ticagrelor) had been approved in the U.S. to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease (CAD), the most common type of heart disease.

 

U.S. P2Y12 Inhibitors Market– Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) pandemic and lockdown in various countries across the globe has impacted the financial status of businesses in all sectors. Private healthcare sector is one of the sectors, which is majorly impacted by the COVID-19 pandemic. Moreover, coronavirus pandemic has negatively impacted the development, production, and supply of pharmaceutical products and affected growth of the severe oral mucositis medications businesses of various companies, across the regions such as North America, as COVID 19 pandemic has led to unprecedented lockdown in several countries such as the U.S. This lockdown has resulted in closure of industrial establishments, except manufacturing of essential commodities, and disruption in supply chain of the pharmaceutical products. Thus, COVID-19 pandemic has affected the economy in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) by its financial impact on firms and financial markets. Supply chain and manufacturing activities in India, Italy, Spain, the U.K., and the U.S. have been disrupted due to lockdowns implemented by governments in the past few months, while countries such as Brazil, France, Russia, Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drug products. Due to severe shortage of medical resources at the front line, only patients diagnosed with serious conditions can be hospitalized. Unfortunately, the pathogenic mechanism of the virus has not been identified completely, though, there is presence of vaccines and drugs manufactured by the companies for prevention and treatment of COVID-19. The COVID-19 pandemic has impacted the global economy and in turn, the U.S. P2Y12 inhibitors market.

 U.S. P2Y12 Inhibitors Market: Restraint

The major factors that may hinder growth of the U.S. P2Y12 inhibitors market include potential side effects of drugs. For instance, side effects of  P2Y12 inhibitors include diarrhea, itching, nausea, skin rash, and stomach pain. Moreover, ticlopidine may lead to a very low white blood cell count or an immune disorder that destroys platelets. Ticagrelor may cause episodes of shortness of breath.

Key Players

Major players operating in the U.S. P2Y12 inhibitors market include Mylan N.V., Bristol-Myers Squibb, Dr Reddy's Laboratories, Teva Pharmaceuticals USA, Inc., AstraZeneca, Genentech,  Eli Lilly and Company,  Panacea Biotec,  CHIESI USA, Inc., Lupin, Cipla, and Biocon.

P2Y12 receptor blockers are group of antiplatelet drugs. Antiplatelet are medicines that stop cells in the blood (platelets) from sticking together and forming a clot. A blood clot can lead to a heart attack or stroke. The P2Y12 receptor is a key player in platelet activation and represents an effective pharmacological target for the inhibition of platelet aggregation and prevention of atherothrombotic events. P2Y12 receptor blocker includes clopidogrel, ticlopidine, ticagrelor, prasugrel, and cangrelor drugs

Market Dynamics

Increasing prevalence of cardiovascular disease is expected to drive the market growth during the forecast period. For instance, according to data published in March 2019  by Florida Department of Health, responsible for the regulation of health practitioners for the preservation of the health, safety, and welfare of the public, stated that heart disease accounts for about two out of 10 deaths in Florida. Moreover, there were 80,402 coronary heart disease hospitalizations (including both angina and myocardial infarction) or an average of 220 coronary heart disease hospitalizations each day in 2018. Increasing government initiative to spread awareness regarding cardiovascular diseases is expected to drive the market growth over the forecast period. For instance, Million Hearts 2022, a national initiative co-led by Centers for Disease Control and Prevention and the Centers for Medicare & Medicaid Services to prevent one million heart attacks and strokes in five years. Moreover, the initiative focuses partner actions on a small set of priorities selected for their impact on heart disease, stroke, and related conditions.

Key features of the study:

  • This report provides in-depth analysis of the U.S. P2Y12 inhibitors market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the U.S. P2Y12 inhibitors market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Mylan N.V., Bristol-Myers Squibb, Dr Reddy's Laboratories, Teva Pharmaceuticals USA, Inc., AstraZeneca,   Genentech, Eli Lilly and Company, Panacea Biotec, CHIESI USA, Inc., Lupin, Cipla, and Biocon
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The U.S. P2Y12 inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. P2Y12 inhibitors market

Detailed Segmentation:

  • U.S. P2Y12 Inhibitors Market, By Drug :
    • Clopidogrel
    • Ticlopidine
    • Ticlopidine
    • Prasugrel
    • Cangrelor
    • Others
  • U.S. P2Y12 Inhibitors Market, By Route of Administration :
    • Oral
    • Intravenous
  • U.S. P2Y12 Inhibitors Market, By Application :
    • Angioplasty
    • Arterial Thrombosis
    • Percutaneous Coronary Interventions
    • Myocardial Infarction
    • Others
  • U.S. P2Y12 Inhibitors Market, By Distribution Channel :
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Company Profiles
    • Mylan N.V.*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Bristol-Myers Squibb
    • Dr Reddy's Laboratories
    • Teva Pharmaceuticals USA, Inc.
    • AstraZeneca
    • Genentech
    • Eli Lilly and Company
    • Panacea Biotec
    • CHIESI USA, Inc.
    • Lupin
    • Cipla
    • Biocon

 “*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The U.S. P2Y12 inhibitors market is estimated to have around US $ 215.7 Mn in 2021, and expected to exhibit a CAGR of 3.8% between 2021 and 2028.
The rising incidence of cardiovascular diseases and increasing product approvals is expected to drive the market growth during the forecast period.
Clopidogrel segment is expected to hold a major market share in the market over the forecast period.
The major factors hampering growth of the market include potential side effects of drugs.
Major players operating in the market include Mylan N.V., Bristol-Myers Squibb, Dr Reddy's Laboratories, Teva Pharmaceuticals USA, Inc.,  AstraZeneca, Genentech, Eli Lilly and Company, Panacea Biotec, CHIESI USA, Inc.,   Lupin, Cipla, and Biocon.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo